Uniplan Investment Counsel, Inc. Arrowhead Pharmaceuticals, Inc. Transaction History

Uniplan Investment Counsel, Inc.

$1.1 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$62.15 - $90.32 $2.52 Million - $3.66 Million	-40,469 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$61.35 - $90.47 $2.16 Million - $3.19 Million	-35,283 Reduced 46.58%	40,469 $2.68 Million
Q4 2020 Feb 12, 2021	SELL	$43.82 - $85.37 $59,419 - $115,761	-1,356 Reduced 1.76%	75,752 $5.81 Million
Q3 2020 Nov 13, 2020	BUY	$33.21 - $51.27 $48,918 - $75,520	1,473 Added 1.95%	77,108 $3.32 Million
Q2 2020 Aug 14, 2020	SELL	$26.12 - $43.27 $33,668 - $55,775	-1,289 Reduced 1.68%	75,635 $3.27 Million
Q1 2020 May 15, 2020	BUY	$20.56 - $63.12 $226,118 - $694,193	10,998 Added 16.68%	76,924 $2.21 Million
Q4 2019 Feb 14, 2020	SELL	$28.14 - $73.01 $1.96 Million - $5.09 Million	-69,773 Reduced 51.42%	65,926 $4.18 Million
Q3 2019 Nov 14, 2019	SELL	$26.26 - $34.86 $188,756 - $250,573	-7,188 Reduced 5.03%	135,699 $3.82 Million
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $4.06 Million - $6.71 Million	-232,867 Reduced 61.97%	142,887 $3.79 Million
Q1 2019 May 15, 2019	SELL	$12.05 - $20.18 $814,833 - $1.36 Million	-67,621 Reduced 15.25%	375,754 $6.9 Million
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $183,095 - $335,845	-17,048 Reduced 3.7%	443,375 $5.51 Million
Q3 2018 Nov 13, 2018	SELL	$14.0 - $20.3 $4.15 Million - $6.02 Million	-296,714 Reduced 39.19%	460,423 $8.83 Million
Q2 2018 Aug 14, 2018	BUY	$6.37 - $14.02 $209,630 - $461,384	32,909 Added 4.54%	757,137 $10.3 Million
Q1 2018 May 14, 2018	BUY	$3.72 - $7.64 $39,082 - $80,265	10,506 Added 1.47%	724,228 $5.22 Million
Q4 2017 Feb 13, 2018	BUY	$3.14 - $4.5 $2.24 Million - $3.21 Million	713,722	713,722 $2.63 Million

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

92.3M

Call Options Held

1.33M

Put Options Held

549K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Uniplan Investment Counsel, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Uniplan Investment Counsel, Inc. with notifications on news.

Account